Please assess the completion status of the following clinical trial:

Trial Title: Double Blind, Placebo-controlled Study of Raloxifene for Negative Symptoms of Schizophrenia in Postmenopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of schizophrenia (DSM-IV criteria)~* Postmenopausal patients. Postmenopause is defined as after a period of one year of spontaneous amenorrhea and a serum follicle stimulating hormone (FSH) level \> 20IU/L.~* Stable doses of their current antipsychotic medication for at least a month prior to study initiation.~* Presence of significant negative symptoms (defined as one or more negative symptom score greater than 4 in the PANSS scale) (Kay 1987)~* Patients have to give written informed consent to participate in the study.~Exclusion Criteria:~* Patients with a substance abuse/dependence diagnosis in the previous six months.~* Mental retardation.~* Endocrine abnormalities, acute or chronic liver disease, impaired kidney function.~* History of thromboembolism, breast cancer, abnormal uterine bleeding, history of cerebrovascular accident.~* Patients taking hormone replacement therapy.~* Patients taking mood stabilizer medication that cannot be discontinued.

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- sugar pill (Type: PLACEBO_COMPARATOR): None
- raloxifene hydrochloride (Type: ACTIVE_COMPARATOR): Dose of raloxifene hydrochloride will be: 60mg /day. Patients are required to continue taking their regular medications throughout the duration of the study. No changes in dose will be required during the study period. Double-blind treatment will continue for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).